We understand that only the most dedicated researchers, world-class facilities, and highest standards in science, quality, and ethics, will deliver the results we need for our patients, and help fulfill more unmet needs. That’s why over the past five years we’ve reinvested over 20% of our revenues into and research and development. Our R&D capabilities are recognized worldwide, from pre-clinical research through all phases of clinical development with proven expertise and focus in cancer care and rare diseases.
Investing in research
Creating an attractive and fulfilling working environment that offers employees opportunities for career advancement, contributes positively to employee satisfaction, which in turn benefits the company. Helsinn reinvests approximately 35 percent of revenues generated into R&D.Learn more about working at Helsinn